

Robust Pipeline Focused on REDs and Deep Brain Disorders

Triplet's Development Pipeline

Program	Indication	Target	Discovery	Preclinical / Translational	Phase 1 / 2	Confirmatory Trial	Global commercial rights
Repeat Expansion Disorders (RED)							
TTX-3360	HD	MSH3	IND/CTA mid-2022				
	SCA1 & SCA3						
	DM1 (CNS)						
	Eval 30+ options						
<i>TTX-3360 backup</i>	HD						
TTX-DM1	DM1 (muscle)						
Non-RED CNS Disorders							
TTX-PD	Parkinson's and Alzheimer's Syndromes	Genetically Validated Targets					
TTX-AD							
Next-Generation Approaches							
Modified oligos	CNS REDs	Validating Multiple Potential Targets					
Gene Editing							
Natural History Studies in Progress							
Study	Indication	Initiation	Site Selection	Enrollment	Follow-Up		
SHIELD ^{HD}	HD						
END-DM1	DM1						
<i>Not Disclosed</i>	<i>Additional indications</i>						



HD = Huntington's disease; SCA = Spinocerebellar ataxia; DM1 = Myotonic dystrophy type 1; AD = Alzheimer's disease; PD = Parkinson's disease